Mycobacterium tuberculosis

Similar documents
Mycobacterium tuberculosis

Characteristics of Mycobacterium

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Fundamentals of Tuberculosis (TB)

Tuberculosis (TB) Fundamentals for School Nurses

Tuberculosis Tools: A Clinical Update

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Treatment of Tuberculosis, 2017

Diagnosis and Treatment of Tuberculosis, 2011

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Descriptive Epidemiology Project: Tuberculosis in the. United States. MPH 510: Applied Epidemiology. Summer A 2014

Questions and Answers About

ESCMID Online Lecture Library. by author

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Symptoms Latent TB Active TB

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Northwestern Polytechnic University

TB the basics. (Dr) Margaret (DHA) and John (INZ)

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Questions and Answers About

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

HEALTH SERVICES POLICY & PROCEDURE MANUAL

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Cooperation. Tuberculosis Panel on Tips from the Field. Introductions. Katie Dickerson, RN. David Miller, RN. Moni Muraki

What Is TB? 388 How TB Is Spread 388 How to Know if a Person Has TB 389 How to Treat TB 389 Resistance to TB medicines 390

TUBERCULOSIS. What you need to know BECAUSE...CARING COMES NATURALLY TO US

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Mycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology

Latent Tuberculosis Best Practices

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

Research in Tuberculosis: Translation into Practice

Running head: TUBERCULOSIS 1

Please distribute a copy of this information to each provider in your organization.

Contact Investigation and Prevention in the USA

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Tuberculosis Populations at Risk

TB BASICS: PRIORITIES AND CLASSIFICATIONS

An Investigation into Tuberculosis Control in India. Disa Linden-Perlis, Karin Wickman, Saya Kato & Ebony Blanch

Diagnosis of drug resistant TB

Photo : Sylvie Ricard. The state of TB in Nunavik

Proposed Regs.pdf

Treatment of Latent TB Infection (LTBI)

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Diagnosis and Medical Management of Latent TB Infection

The treatment of patients with initial isoniazid resistance

Chapter 22. Pulmonary Infections

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Analysis. Answers. Action. Saturday Night Fever. Shaka Brown Capital Congress

#114 - Tuberculosis Update [1]

What is tuberculosis? What causes tuberculosis?

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

Communicable Disease Control Manual Chapter 4: Tuberculosis

Treatment of Tuberculosis

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

Tuberculosis: A Provider s Guide to

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

LESSON ASSIGNMENT. After completing this lesson, you should be able to:

Medical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Michael J. Huey, MD. NYSCHA Annual Meeting WE-2, October 19, 2016

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

TB in Corrections Phoenix, Arizona

TUBERCULOSIS. Famous victims in their intellectual prime: Chopin, Paganini, Thoreau, Keats, Elizabeth Browning, Brontës

Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Primer on Tuberculosis (TB) in the United States

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

MO TASEM AJ Nader Alaridah

PEDIATRIC TB. Modified PPT from group A seminar (F)

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

Tuberculosis: A Persistent Threat to Public Health. A Publication of the HCH Clinicians Network

Laboratory Diagnosis for MDR TB

Tuberculosis Education for the Medical Professional

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Tuberculosis: update 2013

MYCOBACTERIUM. Mycobacterium Tuberculosis (Mtb) nontuberculous mycobacteria (NTM) Mycobacterium lepray

New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease!

NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY

Chapter 08 Lecture Outline

Qian Gao Fudan University

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Treatment of Tuberculosis

Chapter 5 Treatment for Latent Tuberculosis Infection

Application of New Diagnostics and Preventative Treatment in Low and High Burden Settings

Transcription:

Mycobacterium tuberculosis

Mycobacterium tuberculosis Ø small, aerobic, nonmotile bacteria Ø Gram-positive bacillus Ø can survive in a dry state for weeks Ø grow only within the cells of a host organism Ø can be cultured in the laboratory

Mycobacterium tuberculosis Ø spread through the air Ø typically attack the lungs, but TB bacteria can attack any part of the body such as kidney, spine & brain Ø most infections are asymptomatic and latent Ø in latent infections eventually progress to active disease Ø the classic symptoms of active TB infection are a chronic cough with blood-tinged sputum, fever, night sweats & weight loss

Diagnosis Active TB: radiology (x-ray), PCR, microscopic examination, microbiological culture of body fluid M. Tuberculosis (stained red) in sputum Latent TB: skin test and/or blood test

Tuberculosis (TB) Ø /3 of the world s population is thought to have been infected with TB Ø 3.7 million chronic active cases globally in 27 Ø in 2, there were an estimated 8.8 million new cases &.5 million associated deaths, mostly occurring in developing countries Ø no. of TB cases has been decreasing since 26, and new cases have decreased since 22 Ø distribution of TB: 8%: in Asian & Africa Ø 5-% of the US population tested positive

Treatment If not treated properly, TB disease can be fatal latent TB infection treatment Regimens Drugs Duration Isoniazid 9 months Isoniazid 6 months Isoniazid & Rifapentine Rifampin Interval Daily Twice weekly Daily Twice weekly Minimum doses 27 76 8 52 3 months Once weekly 2 4 months Daily 2

Treatment active TB disease treatment regimens Preferred Regimen Initial Phase Alternative Regimen Alternative Regimen Initial Phase Initial Phase Daily INH, RIF, PZA, and EMB* for Thrice- weekly INH, RIF, Daily INH, RIF, PZA, and EMB* 4 doses (2 weeks), then twice PZA, and EMB* for 24 for 56 doses (8 weeks) weekly for 2 doses (6 weeks) doses (8 weeks) Continuation Phase Continuation Phase Continuation Phase Thrice- weekly INH and Daily INH and RIF for 26 Twice- weekly INH and RIF for 36 RIF for 54 doses (8 doses (8 weeks) doses (8 weeks) weeks) or Twice- weekly INH and RIF for 36 doses (8 weeks) INH: isoniazid RIF: rifampin EMB: ethambutol PZA: pyrazinamide

Vaccination BCG (Bacille Calmette-Guérin) Ø often given to infants & small children in countries where TB is common Ø not widely used in US Ø should only be considered for children who have a negative TB skin test

organism chrosome size (Mb) %GC Gene Protein 394 Mycobacterium tuberculosis F 4.42 65.6 3,998 Mycobacterium tuberculosis H37Rv 4.4 65.6 4,62 43 Mycobacterium tuberculosis CCDC579 4.4 65.6 3,695 3646 Mycobacterium tuberculosis CCDC58 4.4 65.6 3,638 359 Mycobacterium tuberculosis CDC55 4.4 65.6 4,293 489 Mycobacterium tuberculosis CTRI-2 4.4 65.6 4, 3944 Mycobacterium tuberculosis H37Ra 4.42 65.6 4,84 434 Mycobacterium tuberculosis H37Rv 4.4 65.6 4,7 4 Mycobacterium tuberculosis KZN 435 4.4 65.6 4,7 459 Mycobacterium tuberculosis KZN 427 4.39 65.6 4,44 3996 www.ncbi.nih.gov/genome/browse TotalB as es : S tdeva T C ontigc ount P er.unknowns P er.l arges ts eq Myc obac terium tuberc ulos is H37R v NC _962 445 Myc obac terium tuberc ulos is C C DC 579 NC _7523 439882 Myc obac terium tuberc ulos is C C DC 58 NC _7522 44598 Myc obac terium tuberc ulos is C DC 55 NC _2755 443837 Myc obac terium tuberc ulos is C TR I- 2 NC _7524 4398525 Myc obac terium tuberc ulos is F NC _9565 4424435 Myc obac terium tuberc ulos is H37R a NC _9525 449977 Myc obac terium tuberc ulos is H37R v NC _843 4478 Myc obac terium tuberc ulos is K ZN435 NC _2943 439825 Myc obac terium tuberc ulos is K ZN427 NC _6768 4394985

M. tuberculosis CCDC579 Genome Atlas

replic on of c hros omes # of rr NA operons Myc obac terium tuberc ulos is H37R v NC _962 Myc obac terium tuberc ulos is C C DC 579 NC _7523 Myc obac terium tuberc ulos is C C DC 58 NC _7522 Myc obac terium tuberc ulos is C DC 55 NC _2755 Myc obac terium tuberc ulos is C TR I- 2 NC _7524 Myc obac terium tuberc ulos is F NC _9565 Myc obac terium tuberc ulos is H37R a NC _9525 Myc obac terium tuberc ulos is H37R v NC _843 Myc obac terium tuberc ulos is K ZN435 NC _2943 Myc obac terium tuberc ulos is K ZN427 NC _6768

Phylogenetic tree from 6S rrna alignment Myc obac terium tuberc ulos is F NC _9565 Myc obac terium tuberc ulos is H37R v NC _843 Myc obac terium tuberc ulos is C C DC 579 NC _7523 Myc obac terium tuberc ulos is K ZN427 NC _6768 Myc obac terium tuberc ulos is C DC 55 NC _2755 Myc obac terium tuberc ulos is C TR I- 2 NC _7524 Myc obac terium tuberc ulos is C C DC 58 NC _7522 Myc obac terium tuberc ulos is K ZN435 NC _2943 Myc obac terium tuberc ulos is H37R a NC _9525 Myc obac terium tuberc ulos is H37R v NC _962

Alignment result for 6S rrna (52 bp)

% A T % G C Myc obac terium tuberc ulos is H37R v NC _962 34.39% 65.6% Myc obac terium tuberc ulos is C C DC 579 NC _7523 34.39% 65.6% Myc obac terium tuberc ulos is C C DC 58 NC _7522 34.4% 65.59% Myc obac terium tuberc ulos is C DC 55 NC _2755 34.39% 65.6% Myc obac terium tuberc ulos is C TR I- 2 NC _7524 34.4% 65.6% Myc obac terium tuberc ulos is F NC _9565 34.38% 65.62% Myc obac terium tuberc ulos is H37R a NC _9525 34.39% 65.6% Myc obac terium tuberc ulos is H37R v NC _843 34.38% 65.62% Myc obac terium tuberc ulos is K ZN435 NC _2943 34.39% 65.6% Myc obac terium tuberc ulos is K ZN427 NC _6768 34.39% 65.6%

M. tuberculosis CCDC579 Amino acid & codon usage

# gene predic ted # gene in gbk Myc obac terium tuberc ulos is H37R v NC _962 486 429 Myc obac terium tuberc ulos is C C DC 579 NC _7523 49 4232 Myc obac terium tuberc ulos is C C DC 58 NC _7522 46 448 Myc obac terium tuberc ulos is C DC 55 NC _2755 479 424 Myc obac terium tuberc ulos is C TR I- 2 NC _7524 473 46 Myc obac terium tuberc ulos is F NC _9565 485 428 Myc obac terium tuberc ulos is H37R a NC _9525 449 438 Myc obac terium tuberc ulos is H37R v NC _843 478 422 Myc obac terium tuberc ulos is K ZN435 NC _2943 479 423 Myc obac terium tuberc ulos is K ZN427 NC _6768 465 49

Blast Matrix

Blast Atlas F CDC55 H37Rv_962 H37Rv_843 CTRI-2 CCDC579 CCDC58 KZN427 KZN435

Pancore plot orgsnism Mycobacterium tuberculosis H37Rv 2 Mycobacterium tuberculosis CDC55 TotalBases gene NC_962 445 486 NC_2755 443837 479 3 Mycobacterium tuberculosis H37Ra 4 Mycobacterium tuberculosis F NC_9525 449977 449 NC_9565 4424435 485 5 Mycobacterium tuberculosis KZN435 6 Mycobacterium tuberculosis KZN427 NC_2943 439825 479 NC_6768 4394985 465 7 Mycobacterium tuberculosis CCDC58 8 Mycobacterium tuberculosis CCDC579 9 Mycobacterium tuberculosis CTRI-2 NC_7522 44598 46 Mycobacterium tuberculosis H37Rv NC_7523 439882 49 NC_7524 4398525 473 NC_843 4478 478

PanGome Tree Mycobacterium tuberculosis CCDC58 NC_7522 Mycobacterium tuberculosis CCDC579 NC_7523 Mycobacterium tuberculosis KZN427 NC_6768 Mycobacterium tuberculosis KZN435 NC_2943 Mycobacterium tuberculosis CTRI-2 NC_7524 Mycobacterium tuberculosis F NC_9565 Mycobacterium tuberculosis H37Rv NC_962 Mycobacterium tuberculosis H37Rv NC_843 Mycobacterium tuberculosis H37Ra NC_9525 Mycobacterium tuberculosis CDC55 NC_2755